• Evenity, a monoclonal antibody that binds and inhibits sclerostin, is a novel bone forming agent with a dual effect on bone, increasing bone formation and decreasing bone resorption1
• Superior fracture risk reduction when used for 12 months followed by alendronate vs alendronate alone in new vertebral, clinical and non-vertebral fractures, including hip1-2
• Rapid and superior improvement in BMD vs alendronate1-2 and teriparatide3 in just 12 months

References:
1. EVENITY® (romosozumab) Malaysia Full Prescribing Information MYEVEPI01, revised May 2021.
2. Saag KG, et al. N Engl J Med 2017; 377:1417-1427.
3. Langdahl BL, et al. Lancet 2017; 390:1585-1594.